Market closed
QIAGEN/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
$QGEN
Sector
Trading on
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,700
Website
QIAGEN Metrics
BasicAdvanced
$8.5B
106.49
$0.37
0.36
-
Price and volume
Market cap
$8.5B
Beta
0.36
52-week high
$45.05
52-week low
$37.63
Average daily volume
1.3M
Financial strength
Current ratio
3.605
Quick ratio
2.763
Long term debt to equity
37.509
Total debt to equity
39.008
Interest coverage (TTM)
11.38%
Management effectiveness
Return on assets (TTM)
5.28%
Return on equity (TTM)
2.27%
Valuation
Price to earnings (TTM)
106.486
Price to revenue (TTM)
4.476
Price to book
2.46
Price to tangible book (TTM)
10.45
Price to free cash flow (TTM)
17.626
Growth
Revenue change (TTM)
0.66%
Earnings per share change (TTM)
-76.42%
3-year revenue growth (CAGR)
-4.22%
3-year earnings per share growth (CAGR)
-45.95%
QIAGEN News
AllArticlesVideos
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
Business Wire·1 week ago
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
Business Wire·2 weeks ago
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $8.5B as of March 14, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 106.49 as of March 14, 2025.
Does QIAGEN stock pay dividends?
No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next QIAGEN dividend payment date?
QIAGEN (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.